Advanced search×


Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Proquest, Rcgp, CSA, Ingenta, Wiley from 1948, Gale, and Ovid from 2005

  1. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.

    Cancer 117(10):2136 (2011) PMID 21523726

    In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM). The authors analyzed the prognostic value of deletion del(13q14), del(17p13), +1...
  2. Psychological, social, and behavioral issues for young adults with cancer.

    Cancer 117(10 Suppl):2289 (2011) PMID 21523748

    Theories of human development suggest that, although all cancer patients experience a common set of life disruptions, they experience them differently, focus on different issues, and attach different levels of importance to different aspects of the experience depending on the time in life at whi...
  3. Treatment of cancer in adolescents and young adults: is affordability a concern?

    Cancer 117(10 Suppl):2258 (2011) PMID 21523743

    Progress in the treatment of cancers in young people has resulted in an increasing success rate in curing the different forms of malignant diseases. The mission of the CPAC/C(17) Task Force on Adolescents and Young Adults (AYA) with cancer is to ensure prompt, equitable access to the best care; ...
  4. Screening for cancer in children, adolescents, and young adults: questions--and more questions.

    Cancer 117(10 Suppl):2275 (2011) PMID 21523746

    Cancer screening interventions offer the potential for both risk and benefit. Research related to screening and cancer in children or adolescents/young adults (AYA) can approach any of several questions. One question to be addressed is whether population-based screening tests can be developed th...
  5. Cancer genome variation in children, adolescents, and young adults.

    Cancer 117(10 Suppl):2262 (2011) PMID 21523744

    This mini-review describes the rapid changes in genome technologies that are leading to comprehensive views of genetic alterations in cancer, and presents high-level thoughts on ways to accelerate translation into clinical medicine. Issues that are more relevant to children, adolescents, and you...
  6. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.

    Cancer 117(10):2156 (2011) PMID 21523728

    ABCG2 protein overexpression and FLT3 internal tandem duplication (ITD) correlate with higher relapse rate and shorter disease-free survival (DFS) in acute myeloid leukemia (AML), but no data are available on the possible effect of concomitant presence of these 2 factors. The authors analyzed th...
  7. The cancer is over, now what?: Understanding risk, changing outcomes.

    Cancer 117(10 Suppl):2250 (2011) PMID 21523742

    About 26,000 adolescents and young adults ages 15 to 29 years are diagnosed with invasive cancer each year. Although >80% will survive beyond 5 years from their cancer diagnosis, many will develop serious morbidity or die prematurely secondary to health problems in part related to their cancer t...
  8. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.

    Cancer 117(10):2024 (2011) PMID 21523713 PMCID PMC4521590

    Estrogen receptor (ER) remains one of the most important biomarkers for breast cancer subtyping and prognosis, and comparative genome hybridization has greatly contributed to the understanding of global genetic imbalance. The authors used single-nucleotide polymorphism (SNP) arrays to compare ov...
  9. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.

    Cancer 117(10):2178 (2011) PMID 21523731

    The objective of this study was to investigate the efficacy of simvastatin in combination with irinotecan and cisplatin in chemotherapy-naive patients with extensive-disease small-cell lung cancer (ED-SCLC). In this phase 2 study, 61 patients received treatment with irinotecan (65 mg/m(2) ) and ...
  10. NCI, Cooperative Groups gear up for changes in clinical trials system: new policies initiated in response to institute of medicine report.

    Cancer 117(10):2017 (2011) PMID 21523709